secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERUS CORP (CERS)
CIK:        0001020214
Form:       8-K
Filed at:   2026-04-30T23:59:59+00:00
Accession:  0001193125-26-197129
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cerus Q1 revenue up 23% to $59.9M, raises FY product revenue guidance
---------------------------------------------------------------------

- Product revenue $53.7M (+24% YoY); total revenue $59.9M (+23% YoY).
- Net loss improved to $1.6M ($0.01/sh) from $7.7M ($0.04/sh) a year ago; Non-GAAP adjusted EBITDA $4.0M vs $0.2M.
- Raises full-year 2026 product revenue guidance to $227M-$231M (was $224M-$228M); IFC revenue guided $22M-$24M.
- Signed 4-year supply agreement with Établissement Français du Sang (EFS) for INTERCEPT Blood System and INT200.
- CEO transition: COO Vivek Jayaraman to become CEO effective July 1, 2026; current CEO William Greenman to become executive chairman.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1020214/000119312526197129/0001193125-26-197129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1020214/000119312526197129/cers-20260430.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-197129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer